Univariate and multivariate analysis of factors affecting OS
| Factor . | P value; hazard ratio (95% confidence interval) . | ||
|---|---|---|---|
| Univariate . | Multivariate at baseline* . | Multivariate for 3 mo landmark analysis* . | |
| Renal involvement | .89; 1.01 (0.78-1.91) | ||
| Liver involvement | .034; 1.3 (1.02-1.8) | .79; 1.04 (0.73-1.5) | .33; 0.6 (0.6-52.3) |
| Presence of CHF | .031; 1.7 (1.05-2.9) | .90; 1.09 (0.26-4.6) | |
| NYHA class | |||
| NYHA 1-2 | .39; 1.2 (0.7-1.9) | .98; 0.98 (0.24-4.0) | .14; 0.53 (0.23-1.2) |
| NYHA 3-4 | .06; 1.4 (0.9-2.2) | .86; 0.89 (0.22-3.4) | .28; 0.69 (0.35-1.3) |
| dFLC | |||
| dFLC (> or ≤180)† | .002; 1.5 (1.17-2.0) | .28; 1.2 (0.85-1.6) | |
| dFLC (< or ≥289 mg/L)† | .17; 1.1 (1.07-3.1) | .26; 1.2 (0.98-2.4) | |
| dFLC (< or ≥500 mg/L) | .003; 1.15 (1.1-1.9) | .21; 1.1 (0.8-1.9) | |
| SBP (as continuous variable) | <.0001; 0.98 (0.98-0.99) | ||
| SBP (>100 mm or ≤100 mm) | <.0001; 1.6 (1.2-2.1) | .001; 1.7 (1.6-3.05) | .017; 1.9 (1.1-3.2) |
| NT-proBNP (< or ≥8500 ng/L) | <.0001; 2.4 (1.8-3.1) | <.001; 2.2 (1.2-2.3) | .001; 2.3 (1.4-3.8) |
| Mean LV wall thickness | .66; 1.06 (0.096-1.05) | ||
| Hematologic response | |||
| CR | Ref | ||
| PR | .025; 2.6 (1.1-6.4) | ||
| NR | <.0001; 7.3 (3.1-16) | ||
| Factor . | P value; hazard ratio (95% confidence interval) . | ||
|---|---|---|---|
| Univariate . | Multivariate at baseline* . | Multivariate for 3 mo landmark analysis* . | |
| Renal involvement | .89; 1.01 (0.78-1.91) | ||
| Liver involvement | .034; 1.3 (1.02-1.8) | .79; 1.04 (0.73-1.5) | .33; 0.6 (0.6-52.3) |
| Presence of CHF | .031; 1.7 (1.05-2.9) | .90; 1.09 (0.26-4.6) | |
| NYHA class | |||
| NYHA 1-2 | .39; 1.2 (0.7-1.9) | .98; 0.98 (0.24-4.0) | .14; 0.53 (0.23-1.2) |
| NYHA 3-4 | .06; 1.4 (0.9-2.2) | .86; 0.89 (0.22-3.4) | .28; 0.69 (0.35-1.3) |
| dFLC | |||
| dFLC (> or ≤180)† | .002; 1.5 (1.17-2.0) | .28; 1.2 (0.85-1.6) | |
| dFLC (< or ≥289 mg/L)† | .17; 1.1 (1.07-3.1) | .26; 1.2 (0.98-2.4) | |
| dFLC (< or ≥500 mg/L) | .003; 1.15 (1.1-1.9) | .21; 1.1 (0.8-1.9) | |
| SBP (as continuous variable) | <.0001; 0.98 (0.98-0.99) | ||
| SBP (>100 mm or ≤100 mm) | <.0001; 1.6 (1.2-2.1) | .001; 1.7 (1.6-3.05) | .017; 1.9 (1.1-3.2) |
| NT-proBNP (< or ≥8500 ng/L) | <.0001; 2.4 (1.8-3.1) | <.001; 2.2 (1.2-2.3) | .001; 2.3 (1.4-3.8) |
| Mean LV wall thickness | .66; 1.06 (0.096-1.05) | ||
| Hematologic response | |||
| CR | Ref | ||
| PR | .025; 2.6 (1.1-6.4) | ||
| NR | <.0001; 7.3 (3.1-16) | ||
CHF, congestive heart failure; Ref, reference.
Highly significant P values are in bold.
Separate multivariate models were generated for all patients at baseline, and a landmark analysis was done at 3 months for those patients who were assessable for response to treatment at/after 3 months.
Separate multivariate models were generated using dFLC > or ≤180 mg/L, dFLC < or ≥289 mg/L, and dFLC < or ≥500 mg/L.